31/01/2018 - Research

The IGTP leads the biological and pathological studies in an international clinical trial focused on child and adolescent liver tumours

It is the first and largest international clinical trial ever in this type of patients. IGTP researchers coordinate what is going to be a unique collection in Europe of biological samples for this segment of patients, and will lead the posterior studies. Liver cancer in children is classified as a rare diseases and, in Spain, 15 cases are diagnoses every year.

23/01/2018 - Research

The new Spin-off Ahead Therapeutics SL, will develop new therapies for auto-immune diseases

The spin-off is the result of a joint research project between the IGTP, ICN2 and ICREA and has already attracted 1.1 million euros. The Catalan biotech company has been created to develop the therapies for clinical use. The therapy uses liposomes to halt the destructive reaction of the body's own tissues caused by diseases such as Type 1 diabetes or multiple sclerosis.

17/01/2018 - Research

Germans Trias surgeons devise Rutilight® to improve illumination during operations.

The spin-off company Swan Medical SL, of which the IGTP is a shareholder, is responsible for production and distribution of the product, baptised Rutilight®, that can be adapted to all current surgical instruments to provide a spotlight on the operating area. The new device eliminates shadows in the operating area and illuminates places that are difficult to access. The tool has been invented by surgeons for surgeons

11/01/2018 - Research

Examination of skin plaques by a paediatric dermatologist has been confirmed as a reliable way to diagnose NF2 in children before symptoms appear

IGTP Scientists working with the Reference Centre for Phakomatoses in the Germans Trias i Pujol Hospital-ICO Badalona have confirmed what dermatologists on the team have long suspected.  Skin plaques in young children can be used to identify NF2 patients long before their symptoms appear.

21/12/2017 - Research

Researchers find a novel mechanism to decrease inflammation and promote tissue regeneration after a heart attack

Researchers from the Germans Trias i Pujol Research Institute (IGTP) have described a new mechanism of mesenychymal stem cells for the modulation of the immune response seen in vitro and in a translational model for heart attack in pigs. 

23/10/2017 - Research

Una nova teràpia gènica desenvolupada per l’IGTP evita l’aparició de l’Atàxia de Friedreich i prevé els seus signes associats

La fase preclínica del projecte, iniciada al 2014, es va finançar a través d'un programa de micromecenatge. Aquest dissabte s'han presentat els resultats a totes les persones i entitats que han col·laborat en el programa.

09/10/2017 - Research

MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption

A new paper published by researchers from the Josep Carreras Leukaemia Research Institute (IJC) and the Programme of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP) reveals a new role for macroH2A1.1. The project was spear-headed by Melanija Posavec Marjanovic and Sarah Hurtado-Bagès, two PhD students enrolled in the Pompeu Fabra University PhD program

25/01/2017 - Research

A new way to diagnose hereditary cancers is already benefitting patients in the Catalan Health Service thanks to ground-breaking research by the Joint Program on Hereditary Cancer ICO-IDIBELL-IGTP

Researchers of the Joint Program on Hereditary Cancer ICO-IDIBELL-IGTP have designed and tested a new strategy based on next generation sequencing (NGS) for the genetic diagnostics of hereditary cancer. They tested it against other current commercially available NGS methods and the new method gave  better results. Previously patients were only tested for one or a small number of genes but now each patient can be tested for a wide range of genes in one single step and the results analysed using complex computing tools resulting in a much more efficient diagnostic process.  700 patients in the Catalan Health System have already benefitted from the new diagnostic approach

The Patients’ Association Chromo22 raises 50,000 euros for research into Neurofibromatosis Type 2

On 22 December the patients' association Chromo22 signed an agreement with the IGTP in which they formalize a donation of 50,000 euros for research into Neurofibromatosis Type 2 (NF2)

20/12/2016 - Research

IGTP Scientists at the IGTP discover new clues as to the role of "junk DNA"

Half the human genome is made up of repeated sequences that are often called "junk DNA", because up until now, little is known on what function they had.